Travere Therapeutics' Shares Hit 52-Week High After Swing to 3Q Profit

Dow Jones10-31

By Nicholas G. Miller

Shares of Travere Therapeutics rose after the company beat analysts' expectations in swinging to a third-quarter profit.

The stock rose 14% to $33.67, and at one point touched a new 52-week high of $35 in Friday morning training. Shares are up 93% this year.

The pharmaceutical company swung to a profit of $25.7 million, or 28 cents a share, compared with a loss of $54.8 million, or 70 cents a share, the year prior.

Adjusted earnings were 59 cents a share. Analysts expected a loss of 5 cents a share, according to FactSet.

Net product sales rose to $113.2 million from $61 million, fueled by sales growth for its Filspari kidney disease drug. Wall Street expected $105.2 million.

Write to Nicholas G. Miller at nicholas.miller@wsj.com.

(END) Dow Jones Newswires

October 31, 2025 11:39 ET (15:39 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2579794496?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-31 23:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579794496","market":"fut","top_or_hot":-1,"title":"Travere Therapeutics' Shares Hit 52-Week High After Swing to 3Q Profit","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Nicholas G. Miller \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Travere <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> rose after the company beat analysts' expectations in swinging to a third-quarter profit. \n</p>\n<p>\n  The stock rose 14% to $33.67, and at one point touched a new 52-week high of $35 in Friday morning training. Shares are  up 93% this year. \n</p>\n<p>\n  The pharmaceutical company swung to a profit of $25.7 million, or 28 cents a share, compared with a loss of $54.8 million, or 70 cents a share, the year prior. \n</p>\n<p>\n  Adjusted earnings were 59 cents a share. Analysts expected a loss of 5 cents a share, according to FactSet. \n</p>\n<p>\n  Net product sales rose to $113.2 million from $61 million, fueled by sales growth for its Filspari kidney disease drug. Wall Street expected $105.2 million. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 31, 2025 11:39 ET (15:39 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Travere Therapeutics' Shares Hit 52-Week High After Swing to 3Q Profit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTravere Therapeutics' Shares Hit 52-Week High After Swing to 3Q Profit\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-31 23:39</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Nicholas G. Miller \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Travere <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> rose after the company beat analysts' expectations in swinging to a third-quarter profit. \n</p>\n<p>\n  The stock rose 14% to $33.67, and at one point touched a new 52-week high of $35 in Friday morning training. Shares are  up 93% this year. \n</p>\n<p>\n  The pharmaceutical company swung to a profit of $25.7 million, or 28 cents a share, compared with a loss of $54.8 million, or 70 cents a share, the year prior. \n</p>\n<p>\n  Adjusted earnings were 59 cents a share. Analysts expected a loss of 5 cents a share, according to FactSet. \n</p>\n<p>\n  Net product sales rose to $113.2 million from $61 million, fueled by sales growth for its Filspari kidney disease drug. Wall Street expected $105.2 million. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 31, 2025 11:39 ET (15:39 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2579794496","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579794496","pubTimestamp":1761925140,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Travere Therapeutics rose after the company beat analysts' expectations in swinging to a third-quarter profit.The stock rose 14% to $33.67, and at one point touched a new 52-week high of $35 in Friday morning training. Shares are  up 93% this year.The pharmaceutical company swung to a profit of $25.7 million, or 28 cents a share, compared with a loss of $54.8 million, or 70 cents a share, the year prior.Adjusted earnings were 59 cents a share. Analysts expected a loss of 5 cents a share, according to FactSet.Net product sales rose to $113.2 million from $61 million, fueled by sales growth for its Filspari kidney disease drug. Wall Street expected $105.2 million.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","TVTX":"Travere Therapeutics, Inc.","LENZ":"Therapeutics","BK4007":"制药","BK4139":"生物科技"},"translate_title":"Travere Therapeutics股价在第三季度盈利后触及52周高点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TVTX":0.9,"LENZ":1.5},"content_text":"By Nicholas G. Miller \n\n\n \n\n\n  Shares of Travere Therapeutics rose after the company beat analysts' expectations in swinging to a third-quarter profit. \n\n\n  The stock rose 14% to $33.67, and at one point touched a new 52-week high of $35 in Friday morning training. Shares are  up 93% this year. \n\n\n  The pharmaceutical company swung to a profit of $25.7 million, or 28 cents a share, compared with a loss of $54.8 million, or 70 cents a share, the year prior. \n\n\n  Adjusted earnings were 59 cents a share. Analysts expected a loss of 5 cents a share, according to FactSet. \n\n\n  Net product sales rose to $113.2 million from $61 million, fueled by sales growth for its Filspari kidney disease drug. Wall Street expected $105.2 million. \n\n\n \n\n\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 31, 2025 11:39 ET (15:39 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2579794496","isCrawlerRequest":true}